X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Knoll Pharma:1QFY03 net up 53% - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 2, 2002

    Knoll Pharma:1QFY03 net up 53%

    Knoll Pharmaceuticals, (now a subsidiary of Abott Labs) has registered marginal decline in sales for 1QFY03. However, a sharp rise in operating margins helped the company register a 53% rise in profits. Knoll Pharma is a leading player in the domestic insulin, anti-diabetic, pain control and antacid market.

    (Rs m) 1QFY02 1QFY03 % Change
    Sales 813 802 -1.4%
    Other Income 25 48 92.0%
    Expenditure 701 643 -8.2%
    Operating Profit (EBDIT) 112 159 41.5%
    Operating Profit Margin (%) 13.8% 19.8%
    Interest 1 0 -70.0%
    Depreciation 11 15 40.0%
    Profit before Tax 125 191 52.6%
         
    Tax 33 50 51.5%
    Profit after Tax/(Loss) 92 141 53.0%
    Net profit margin (%) 11.3% 17.6%  
    No. of Shares (eoy) (m) 16.2 16.2  
    Diluted Earnings per share* 22.7 34.8  
    P/E (at current price) 13.3 8.7  
    (*- annualised)      

    The rise in operating margins is on account of two reasons. The current year's financials received a boost on account of upward revision in prices of four formulations of insulin by NPPA last September. Secondly, last year, the company profits dipped following a cut in Ibuprofen prices by NPPA. Ibuprofen is a bulk drug used in pain management segment. As Knoll Pharma is a market leader in Ibuprofen market, the price cut had a severe impact on the company's financials in 1QFY02.

    Knoll Pharmaceuticals Ltd had recently announced the buyback of 919,000 fully paid up equity shares from the existing shareholders through a tender offer at a price of Rs 350 per share. This represents around 14% of the free float of the company. However, pending certain regulatory approvals from SEBI, the buyback stands annulled for the time being. The latest available shareholding pattern is as follows:

    Knoll Pharma- Shareholding pattern
    Foreign Colloborators 55.7%
    Domestic Institutions 14.3%
    FII's/ GDR 3.3%
    Freefloat 26.7%

    The stock is currently trading at a P/e multiple of 9x FY02 earnings, a 16% discount to its proposed open offer price. The stock trades at considerable discount to its peers. Knoll Pharma’s financials are expected to look up in the short term, mirroring the Insulin price revision. However, in the long term, competition is expected to set in quickly, threatening the leadership position of the company. Lot of domestic players like Glenmark, Wockhardt and Shanta Bio-tech already have clear plans to enter the insulin market. Considering the size and price of the proposed buyback offer, the stock price is expected to remain range bound in the near term.

     

     

    Equitymaster requests your view! Post a comment on "Knoll Pharma:1QFY03 net up 53%". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    ABBOTT INDIA SHARE PRICE


    Aug 21, 2017 (Close)

    TRACK ABBOTT INDIA

    • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    ABBOTT INDIA 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE ABBOTT INDIA WITH

    MARKET STATS